Is ABMD a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

516 people get ABMD articles and Market Currents by email alert.

Get email alerts on ABMD »

HEADLINES:

Abiomed to Present at Deutsche Bank 38th Annual Health Care Conference

GlobeNewswire (Wed, 8:00AM)
Abiomed to Present at UBS Global Health Care Conference

GlobeNewswire (May 17, 2013)
Abiomed to Present at Bank of America Merrill Lynch 2013 Health Care Conference

GlobeNewswire (May 8, 2013)
Abiomed to Present at Bank of America Merrill Lynch 2013 Smid Cap Conference

GlobeNewswire (May 3, 2013)
ABIOMED CEO Discusses F4Q 2013 Results - Earnings Call Transcript
Thu, May 2
Abiomed Announces Fourth Quarter GAAP EPS of $0.09 on Record Revenue and Patients Supported

GlobeNewswire (May 2, 2013)
Abiomed Announces Publication of Protect II Cost Effectiveness Study in American Health & Drug Benefits Journal

GlobeNewswire (May 1, 2013)
Abiomed Announces Preliminary Fourth Quarter Revenue of $43.7 Million, Driven by Record Number of Patients Supported

GlobeNewswire (Apr 17, 2013)
Abiomed Announces First Impella RP Patient Enrolled in Recover Right Study

GlobeNewswire (Apr 1, 2013)
After Marketing Mishap, Abiomed Still Has A Heartbeat
Pinnacle Insight • Thu, Mar 28 • 1 Comment
HeartWare Is Premium-Priced Growth, But Could Still Go Higher
Stephen Simpson • Thu, Mar 7 • 8 Comments
Abiomed's Impella(R) Technology Showcased at ACC 2013

GlobeNewswire (Mar 7, 2013)
Abiomed to Present at Barclays Global Healthcare Conference

GlobeNewswire (Mar 7, 2013)
Abiomed Announces Several Reimbursement Milestones

GlobeNewswire (Mar 4, 2013)
Abiomed to Present at Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 27, 2013)
Risky Sunshine Heart Looks Very Interesting
Stephen Simpson • Thu, Feb 21 • 15 Comments
Abiomed Receives Close-Out Letter From Food and Drug Administration

GlobeNewswire (Feb 20, 2013)
3 Healthcare Stocks With Bullish Short Trends
Kapitall • Thu, Feb 14
Abiomed to Present at Leerink Swann Global Healthcare Conference 2013

GlobeNewswire (Feb 7, 2013)
Abiomed's CEO Discusses F3Q13 Results - Earnings Call Transcript
Wed, Feb 6

To learn more about Seeking Alpha Pro, click here.

After Marketing Mishap, Abiomed Still Has A Heartbeat
Pinnacle Insight • Thu, Mar 28 • 1 Comment
Compelling Impella: Abiomed May Double Its Revenues
Douglas Cress • Thu, Jun 5, 2008
Abiomed Heart Pump Gets FDA Approval, Shares Jump
Eben Tessari • Mon, Jun 2, 2008
How To Play An Abiomed Long Trade
Michael Michaud • Mon, Jan 21, 2008 • 1 Comment
Clock is Ticking on Approval of Abiomed's Impella
Ian Wyatt • Mon, Aug 13, 2007

HeartWare Is Premium-Priced Growth, But Could Still Go Higher
Stephen Simpson • Thu, Mar 7 • 8 Comments
Risky Sunshine Heart Looks Very Interesting
Stephen Simpson • Thu, Feb 21 • 15 Comments
3 Healthcare Stocks With Bullish Short Trends
Kapitall • Thu, Feb 14
Hedge Funds Are Buying These 5 Highly Shorted And Oversold Stocks
Kapitall • Sat, Jan 19
3 Undervalued Healthcare Stocks With Heavy Institutional Buying
Kapitall • Fri, Dec 21, 2012
9 High-Growth Healthcare Stocks With Bearish Stock Trends
Kapitall • Wed, Dec 19, 2012 • 4 Comments
13 Hammered Stocks Limping Into 2013
Alan Brochstein • Sun, Dec 16, 2012 • 15 Comments
Biotech Weekend Recap: Earnings Reports And Disappointments
Brian L. Wilson • Mon, Nov 5, 2012 • 1 Comment
Best And Worst Performing Stocks On Earnings This Season
Bespoke Investment Group • Sun, Nov 4, 2012 • 3 Comments
Cramer's Lightning Round - Windstream Is Tough (10/25/12)
SA Editor Miriam Metzinger • Fri, Oct 26, 2012 • 4 Comments
3 Small-Cap Growth Stocks With Positive Momentum
Arie Goren • Wed, Oct 3, 2012
6 Highly-Liquid Small-Cap Stocks Headed For Growth
ZetaKap • Wed, Sep 19, 2012
4 Medical Device Stocks Undervalued By EPS Trends
Kapitall • Thu, Sep 6, 2012
2 Healthcare Companies With New Analyst Coverage Growth Investors Should Consider
Matt Schilling • Thu, Aug 30, 2012
8 Highly Liquid Healthcare Stocks Undervalued By EPS Trends
Kapitall • Thu, Aug 23, 2012
5 Low-Debt Healthcare Stocks Positioned For Growth
ZetaKap • Thu, Aug 23, 2012
10 Medical Device Stocks Hedge Funds Are Buying Up
Kapitall • Fri, Aug 17, 2012 • 4 Comments
7 Highly Liquid Hedge Fund Stock Picks Undervalued By Target Price
Kapitall • Tue, Aug 14, 2012 • 1 Comment
5 Medical Device Stocks Undervalued By EPS Trends
Kapitall • Mon, Aug 13, 2012
2 Healthcare Companies Set To Report Earnings With Good Upside Potential
Matt Schilling • Thu, Aug 2, 2012

ABIOMED CEO Discusses F4Q 2013 Results - Earnings Call Transcript
Thu, May 2
Abiomed's CEO Discusses F3Q13 Results - Earnings Call Transcript
Wed, Feb 6
Abiomed's CEO Presents 515i Reclassification Panel Conference Call (Transcript)
Wed, Dec 12, 2012
Abiomed's CEO Discusses F2Q13 Results - Earnings Call Transcript
Thu, Nov 1, 2012 • 2 Comments
ABIOMED's CEO Discusses F1Q13 Results - Earnings Call Transcript
Thu, Aug 2, 2012
Abiomed CEO Discusses Q2 2011 Results - Earnings Call Transcript
Thu, Nov 4, 2010
Abiomed, Inc. F1Q11 (Qtr End 06/30/10) Earnings Call Transcript
Wed, Aug 4, 2010
Abiomed, Inc. Q4 2010 Earnings Call Transcript
Thu, May 20, 2010
Abiomed, Inc. Q3 2009 Earnings Call Transcript
Tue, Feb 17, 2009
Abiomed, Inc., F2Q09 (Qtr End 9/30/08) Earnings Call Transcript
Mon, Nov 10, 2008
Abiomed Inc. Q1 2009 Earnings Call Transcript
Thu, Aug 7, 2008
Abiomed Inc F4Q08 (Qtr End 3/31/08) Earnings Call Transcript
Fri, May 30, 2008
Abiomed Inc. F3Q08 (Qtr End 31/12/07) Earnings Call Transcript
Fri, Apr 11, 2008

Abiomed to Present at Deutsche Bank 38th Annual Health Care Conference

GlobeNewswire (Wed, 8:00AM)
Abiomed to Present at UBS Global Health Care Conference

GlobeNewswire (May 17, 2013)
Abiomed to Present at Bank of America Merrill Lynch 2013 Health Care Conference

GlobeNewswire (May 8, 2013)
Abiomed to Present at Bank of America Merrill Lynch 2013 Smid Cap Conference

GlobeNewswire (May 3, 2013)
Abiomed Announces Fourth Quarter GAAP EPS of $0.09 on Record Revenue and Patients Supported

GlobeNewswire (May 2, 2013)
Abiomed Announces Publication of Protect II Cost Effectiveness Study in American Health & Drug Benefits Journal

GlobeNewswire (May 1, 2013)
Midday Movers: AAPL, QCOM & More

at CNBC.com (Apr 17, 2013)
Abiomed Announces Preliminary Fourth Quarter Revenue of $43.7 Million, Driven by Record Number of Patients Supported

GlobeNewswire (Apr 17, 2013)
Abiomed Announces First Impella RP Patient Enrolled in Recover Right Study

GlobeNewswire (Apr 1, 2013)
After-Hours Buzz: MW, VRA, ETFC & More

at CNBC.com (Mar 13, 2013)
Abiomed's Impella(R) Technology Showcased at ACC 2013

GlobeNewswire (Mar 7, 2013)
Abiomed to Present at Barclays Global Healthcare Conference

GlobeNewswire (Mar 7, 2013)
Abiomed Announces Several Reimbursement Milestones

GlobeNewswire (Mar 4, 2013)
Abiomed to Present at Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 27, 2013)
The Technical Indicator: Charting a volatility spike, and trend shift

at MarketWatch.com (Feb 26, 2013)
Abiomed Receives Close-Out Letter From Food and Drug Administration

GlobeNewswire (Feb 20, 2013)
Abiomed to Present at Leerink Swann Global Healthcare Conference 2013

GlobeNewswire (Feb 7, 2013)
Abiomed Announces Revenue of $38.3 Million, Up 19% and Record Impella Patient Usage, Up 26%

GlobeNewswire (Feb 6, 2013)
Abiomed Third Quarter Fiscal 2013 Earnings and Conference Call Notification

GlobeNewswire (Jan 17, 2013)
Lightning Round: MGM, Colfax & More

at CNBC.com (Dec 12, 2012)

ABMD vs. ETF Alternatives

Company Description

Currently, there's no company description for ABMD.

Sector: Healthcare

Industry: Medical Instruments & Supplies

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 2, 12:57 PM Abiomed (ABMD +6.7%) moves up after Q1 revenues come in well ahead of expectations, lifted by a 22% jump in revenue from its Impella temporary heart product to $36.5M from $29.9M. An additional 30 hospitals purchased the Impella 2.5 during the quarter, bringing the total to 748 customer sites. An additional 55 hospitals purchased the Impella CP, bringing the total number of Impella CP sites to 106. Gross margin slipped to 79.8% from 81.8% Y/Y, while operating margin was 9.5%, compared to 7.9% over the same period. Comment! [Healthcare, Earnings, On the Move]
Thursday, May 2, 7:20 AM Abiomed (ABMD): FQ4 EPS of $0.09. Revenue of $43.7M (+17% Y/Y) beats by $1.75M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, May 2, 12:05 AM Notable earnings before Thursday’s open: ABMD, ACOR, ACT, AEE, ANR, ANSS, ARG, ARQL, ATK, AYR, BDBD, BDX, BEAM, BGCP, BZH, CAH, CEVA, CHD, CI, CME, CNP, CPN, CTRX, DIN, DNR, EL, ELNK, FIG, FLY, FNP, FWLT, GEL, GG, GIL, GM, GNRC, GOLD, HAR, HK, HSH, INCY, INGR, IP, IRDM, IT, ITT, K, LF, LQDT, LXP, MDC, MFC, MGI, MGM, MMC, MMP, MWW, NIHD, NNN, NUS, OCN, OGE, OXF, OZM, PCG, PPL, PWR, PXP, RGLD, RNO, SBH, SFY, SHPG, SNI, SPR, SRE, STRA, TEVA, VMC, VRX, WNR, WPX, WWE, XEL Comment! [Earnings]
Wednesday, May 1, 5:30 PM Notable earnings before Thursday’s open: ABMD, ACOR, ACT, AEE, ANR, ANSS, ARG, ARQL, ATK, AYR, BDBD, BDX, BEAM, BGCP, BZH, CAH, CEVA, CHD, CI, CME, CNP, CPN, CTRX, DIN, DNR, EL, ELNK, FIG, FLY, FNP, FWLT, GEL, GG, GIL, GM, GNRC, GOLD, HAR, HK, HSH, INCY, INGR, IP, IRDM, IT, ITT, K, LF, LQDT, LXP, MDC, MFC, MGI, MGM, MMC, MMP, MWW, NIHD, NNN, NUS, OCN, OGE, OXF, OZM, PCG, PPL, PWR, PXP, RGLD, RNO, SBH, SFY, SHPG, SNI, SPR, SRE, STRA, TEVA, VMC, VRX, WNR, WPX, WWE, XEL Comment! [Earnings]
Wednesday, April 17, 9:12 AM Premarket gainers: VRML +29%. ACUR +26%. OCZ +18%. CUR +9%. ALKS +9%. ABMD +9%. ASML +6%.
Losers: EOPN -29%. INWK -25%. CXW -15%. MHR -12%. ZGNX -11%. TXT -9%. CRUS -7%. VRNG -6%. 1 Comment [On the Move]
Wednesday, April 17, 8:56 AM Abiomed (ABMD) soars 8.7% premarket after announcing preliminary Q4 revenue of $43.7M, representing 17% and 14% Y/Y and sequential top line growth respectively. For FY2013 the company says revenue grew 25% to $158.1M. Analysts were expecting $41.5M for Q4 and $156.04M for the full year. This marks the third straight year ABMD has topped its full year revenue guidance. Comment! [Healthcare, On the Move]
Tuesday, April 9, 1:54 PM Shares of Abiomed (ABMD -3.6%) suffer after Piper Jaffray downgrades the stock to Neutral with a reiterated price target of $18, citing potential drag from FDA premarket approval requirements. On the bright side, "a growing product pipeline [and] the potential for movement into new markets such as Japan … should put a floor under the shares," according to analyst Brooks West. Comment! [Healthcare, On the Move]
Wednesday, February 6, 5:43 PM After-hours top gainers, as of 5:15 p.m.: DV +13%. ZUMZ +8%. WNC +7%. ABMD +6%. LF +6%.
After-hours top losers: AKAM -16%. KFRC -14%. ZOLT -11%. IRBT -9%. PSMI -9%. Comment! [On the Move]
Wednesday, February 6, 3:29 PM Abiomed (ABMD -6.1%) takes a hit after the medical device company missed on its Q4 EPS result earlier this morning, and reaffirmed an FY13 guidance that trails Street expectations. It now forecasts revenue of $155M to $157M, lagging consensus by around $1M. Comment! [Healthcare, Earnings, On the Move]
Wednesday, February 6, 7:03 AM Abiomed (ABMD): FQ3 Gaap EPS of $0.07 misses by $0.05. Revenue of $38.3M (+19% Y/Y) beats by $0.26M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, February 6, 12:05 AM Notable earnings before Wednesday’s open: ABMD, AINV, CMI, CMP, CVH, CVS, ELN, GAS, ICE, IVR, MPEL, MRO, MT, NUS, PLD, RL, TWX, USG, VICL, VMED Comment! [Earnings]
Tuesday, February 5, 5:30 PM Notable earnings before Wednesday’s open: ABMD, AINV, CMI, CMP, CVH, CVS, ELN, GAS, ICE, IVR, MPEL, MRO, MT, NUS, PLD, RL, TWX, USG, VICL, VMED Comment! [Earnings]
Monday, December 17, 2012, 5:39 PM S&P announces some changes to its indices: United Natural Foods (UNFI) will replace Amerigroup (AGP) in the S&P MidCap 400, and Ixia (XXIA) will replace United Natural Foods in the S&P SmallCap 600. Wellpoint (WLP) is acquiring AGP in a deal expected to be completed soon. Abiomed (ABMD) is also to be added to the S&P 600, replacing Cascade (CASC) as of the December 21st close of trading. Toyota Industries is acquiring Cascade, which also should be completed soon. Comment! [Healthcare, Consumer, Financials]
Monday, December 10, 2012, 3:40 PM A group of Democratic Senators have signed a letter urging for a delay in implementing a tax on the medical device industry that is scheduled to go into effect January 1, saying the industry has received little guidance about how to comply with the tax, and is causing significant uncertainty and confusion. The Senators are requesting that a delay be included in the fiscal cliff bill Congress is currently negotiating. 2 Comments
Friday, December 7, 2012, 11:32 AM Abiomed (ABMD -6.4%) trades down today coming off a 2-day trading halt, touching a 52-week low of $11.80 after the company announced that the FDA Circulatory System Devices Panel voted to retain Class III status for the temporary ventricular support devices within the non-roller type cardiopulmonary bypass blood pumps category - which includes ABMD's Impella - rather than the lower-risk Class II category it had hoped for. Comment! [Healthcare, On the Move]
Friday, December 7, 2012, 9:10 AM Premarket gainers: GALE +9%. ACRX +7%.
Losers: AMRN -19%. ABMD -7%. QRE -5%. Comment! [On the Move]

StockConsultant
$ABMD has been strong despite the weak market and is now a bottom confirmed breakout, possible gap entry, stock charts http://goo.gl/IqmCI
Feb 25, 10:27 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

StockConsultant
$ABMD has returned back up to 14.58 and is nearing another breakout test
Feb 13, 1:14 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

FortSumter
$ABMD $MAKO Ugly. Two stocks I like for changing demographics but seems no one else does. No position.....yet.
11/28/12
Reply (1)

• !Report Abuse
View all 1 replies
nsahbti: MAKO to volatile and if I am correct they have no money. I would also like to see more data and some kind of outlook.
11/29/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/RucVa9 Premarket Gainer and Loser for Nov 1st: $JDAS, $HPI, $NEWP, $CMVT, $ABMD
11/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

FortSumter
ABMD Reports tomorrow premrkt. Currently at lower support line. Trends between $19 to $24. Emerging medical technology for cardiac patients.
10/31/12
Reply (1)

• !Report Abuse
View all 1 replies
FortSumter: Having trouble getting medicare reimbursement (just a typical redtape for new treatments). Conference call about re-im could send higher.
10/31/12
• !Report Abuse
Add a reply...

140 characters

ZetaKap
6 Highly-Liquid Small-Cap Stocks Headed For Growth http://bit.ly/Up66qK $ABMD $CMTL $CPAC $HTWR $SLCA $VCRA @ZetaKap
9/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Low-Debt Healthcare Stocks Positioned For Growth http://bit.ly/RGq1mA $ABMD $AUXL $BMTI $GNMK $PHMD @ZetaKap
8/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Prognoticator
With very little competition in near term horizon ABMD's Impella will continue to accelerate adoption as it takes over the Balloon pump mkt
8/2/12
Reply (6)

• !Report Abuse
View all 6 replies
Prognoticator: Agree Fort there is a $20 support.. should fluctuate in near term but 6 month horizon looking to see it pop to 25 - 27 range.
8/22/12
• !Report Abuse
Prognoticator: Agree Fort there is a $20 support.. should fluctuate in near term but 6 month horizon looking to see it pop to 25 - 27 range.
8/22/12
• !Report Abuse
Add a reply...

140 characters

FortSumter
Sold ABMD @$21.81 for a 5% gain over 2 weeks. Great biotech and want long but green is green for now. Re-visit later.
6/7/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

FortSumter
Took a long position in ABMD @$20.80. Disruptive technology for dealing with cardiac issues. Might be early but like the prospects.
6/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

FortSumter
$ABMD $MAKO Ugly. Two stocks I like for changing demographics but seems no one else does. No position.....yet.
11/28/12
Reply (1)

• !Report Abuse
View all 1 replies
nsahbti: MAKO to volatile and if I am correct they have no money. I would also like to see more data and some kind of outlook.
11/29/12
• !Report Abuse
Add a reply...

140 characters

FortSumter
ABMD Reports tomorrow premrkt. Currently at lower support line. Trends between $19 to $24. Emerging medical technology for cardiac patients.
10/31/12
Reply (1)

• !Report Abuse
View all 1 replies
FortSumter: Having trouble getting medicare reimbursement (just a typical redtape for new treatments). Conference call about re-im could send higher.
10/31/12
• !Report Abuse
Add a reply...

140 characters

Prognoticator
With very little competition in near term horizon ABMD's Impella will continue to accelerate adoption as it takes over the Balloon pump mkt
8/2/12
Reply (6)

• !Report Abuse
View all 6 replies
Prognoticator: Agree Fort there is a $20 support.. should fluctuate in near term but 6 month horizon looking to see it pop to 25 - 27 range.
8/22/12
• !Report Abuse
Prognoticator: Agree Fort there is a $20 support.. should fluctuate in near term but 6 month horizon looking to see it pop to 25 - 27 range.
8/22/12
• !Report Abuse
Add a reply...

140 characters

ABMD ABIOMED, Inc.

ABMD

ABIOMED, Inc.